MedTrace Logo

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2025-02-04

No results posted yet for this study

Summary

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

Conditions

  • Solid Tumor, Adult
  • Relapsed Cancer
  • Refractory Cancer

Interventions

DRUG

HST-1011

HST-1011 given orally

BIOLOGICAL

Cemiplimab

Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally

Sponsors & Collaborators

  • HotSpot Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Alison O'Neill, MD · HotSpot Therapeutics, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662397 on ClinicalTrials.gov